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Background. Higher fasting blood glucose (FBG) concentrations in the hyperglycemic range are associated with more severe
strokes. Whether this association also extends into patients with FBG in the normoglycemic range is unclear. We studied the
association of stroke severity and FBG in normoglycemic patients with ischemic stroke in a median of 7 days after stroke when
the initial glycemic stress response has resolved. Method and Material. Included were 361 nondiabetic ischemic stroke patients
with admission fasting blood glucose within 70–130mg/dL admitted into an acute stroke rehabilitation unit in a median of 7
days after stroke. Data including neuroimaging, vital signs, cardiovascular risk factors, and admission functional independence
measure (AFIM) were recorded prospectively. Results. FBG correlated with stroke severity in the normoglycemic 70–130mg/dL
range (FBG-AFIM correlation coeﬃcient −0.17; P = 0.003). Odds ratio for more severe injury (below average AFIM score) was
2.02 for patients with FBG 110–130mg/dL compared to FBG 70–90mg/dL (95% conﬁdence interval 1.10–3.73, P = 0.022). Each
mg/dL increase in FBG was associated with an average decrease of 0.25FIM points. In a multiple linear regression model, FBG was
associated with more severe stroke (P = 0.002). Conclusion. One week after ischemic stroke, FBG within the normoglycemic range
was associated with stroke severity.
1.Introduction
Animalmodelshaveprovidedevidenceofadeleteriouseﬀect
of hyperglycemia on ischemic brain damage [1–5], and
hyperglycemia has been identiﬁed as a predictor of poorer
outcome in an increasing number of observational studies
[6–13]. The mechanism by which elevated blood glucose
augments ischemic brain injury is not fully understood.
The most consistent ﬁnding in experimental ischemic brain
injury is the association of hyperglycemia with accumulation
of lactate and acidosis of the ischemic brain tissue [14–16],
but several other potentially harmful biochemical processes
working alone or in concert have been proposed [1, 2, 14,
17]. For the most part, the fate of the ischemic brain tissue is
determined within the very ﬁrst few hours after the occlusive
event when a large penumbra still prevails [18]. Hence, glu-
cose concentration at the time of the occlusive event may
inﬂuence the metabolic milieu in the penumbra and thereby
the amount of brain tissue undergoing irreversible tissue
necrosis as the result of occlusion.
Blood glucose (BG) is usually increased in the hours after
a stroke most probably as the result of a stress response to the
stroke event [12, 19–21]. However, within a week at least, BG
againdeclinesandreachesastablelevel[19–22].Moststudies
point to an association between initial stroke severity and
hyperglycemia on admission to hospital [7, 23, 24], but there
are no studies on the association between stroke severity
and BG concentrations within the normoglycemic range.
Available studies have hitherto used blood samples drawn
in the hours after stroke when BG is elevated and therefore
do not directly reﬂect BG concentration at the time of the
stroke event [7, 23, 24]. On the premise that FBG measured
about one week after stroke (when the stress response has
resolved) [22] is representative of the patient’s habitual BG
at the time of the stroke we studied the association of stroke
severity and FBG measured about one week after stroke, in2 Stroke Research and Treatment
a cohort of 361 nondiabetic stroke patients with FBG within
the normoglycemic range 70–130mg/dL [25].
2.Methods and Material
The study is based on data from the Burke Rehabilitation
Hospital Stroke Database. This database includes informa-
tion on all patients referred for rehabilitation after stroke
from January 2005 to July 2008. Patients were included in
the rehabilitation program if they were deemed medically
stable, were able to engage in the rehabilitation program,
andhadareasonableexpectationofmakingfunctionalgains.
Admission patient data were recorded prospectively in a
computerized hospital record by rehabilitation team mem-
bers. Data accuracy and security were checked routinely by
the medical records department. The diagnosis of stroke
was based on World Health Organization criteria [26]w i t h
conﬁrmative neuroimaging studies in each case.
For this study, the following data were extracted from the
database:
(i) age, gender, days since stroke, and ethnicity (Cau-
casian/non-Caucasian),
(ii) admission functional independence measure (AFIM)
[27]: AFIM measures mobility, activities of daily liv-
ing, cognition, and functional communication on an
18 (worst)–126 (best) scale,
(iii) admission blood pressure (BP), admission infrared
tympanic membrane temperature,
(iv) cardiovascular risk factors known before admission
or diagnosed during hospital stay: arterial hyperten-
sion, diabetes mellitus, heart disease including previ-
ous myocardial infarction, coronary atherosclerosis,
and cardiac heart failure, atrial ﬁbrillation, and body
mass index (BMI),
(v) laboratory values: fasting plasma BG,
(vi) typeofstrokeaccordingtoCT/MRimaging:ischemic
stroke or hemorrhagic stroke.
Diabetes was diagnosed according to the recommenda-
tions of the American Diabetes Association [25]. Hyper-
glycemia was deﬁned as fasting blood glucose >130mg/dL;
hypoglycemia as blood glucose <70mg/dL.
IncludedinthestudywerenondiabeticpatientswithFBG
in the normal range of 70–130mg/dL. Patients with FBG
outside this range and patients with diabetes were excluded
from the study. Patients admitted more than 30 days after
stroke were not included in the study.
The study was performed as part of continuous quality
improvement (CQI) mandated by the Joint Commission for
Accreditation of Hospitals. The CQI objective was to assess
adequacy of glycemic control on our stroke rehabilitation
units.
2.1. Statistics. The data set was prepared by isolating all
ischemic stroke records in the database [ICD9 codes 433-
434] and then excluding records according to the following
criteria: glucose below 70 or above 130mg/dL or no glucose
value entered, FIM change/day below zero or above 3.5
and days since injury greater than 30 (to exclude atypical
patients), a diagnosis of diabetes or diabetic complications
[ICD9 codes 250, 357, or 362], or any of the following
glucose-lowering medications: Glucophage, Glucophage XR,
Humulin R, Humulin N, Lantus, Diabeta, Glucotrol, Glu-
cotrol XL, and Januvia.
AFIM scores and glucose concentrations in this data
set were not normally distributed according to Shapiro-
Wilk, Anderson-Darling, and Kolmogorov-Smirnov tests of
normality (P values for each normality test were 0.000).
Injuryseverityandglucosescoreswerethereforetransformed
into ranks and into normally distributed values that retained
the original average and standard deviation. Parametric (t-
test, multiple linear regression) and nonparametric (Mann-
Whitney, Kolmogorov-Smirnov) statistical tests were then
employed to determine if glucose-injury severity relation-
ships were signiﬁcant in both original and transformed
data sets at 95% conﬁdence. Parametric and nonparametric
results were similar for the original and each transformed
data set.
Multiple linear regression results (Wessa, 2009, version
1.1.23-r3, Leuven, Belgium and SPSS Statistics ver. 17.0,)
were conﬁrmed by Soft Independent Modelling of Class
Analogy (SIMCA P-12, Umetrics, Kinnelon, NJ, US), a mul-
tivariate analysis method that excludes data components
whichdecreasethecross-validationpredictionaccuracycoef-
ﬁcient (Q2). Multicollinearity that might signiﬁcantly aﬀect
regression results was ruled out by examining variance
inﬂation factors (VIFs) for each independent variable, where
the VIF for each independent variable is 1/(1−R2), and R2 is
the coeﬃcient of determination for the regression equation
relating each independent variable to the other independent
variables. All VIFs were below 1.5, so by this measure of
multicollinearity, there is no reason for concern.
Associations between FBG and days since injury, tem-
perature, PEG (percutaneous endoscopic gastrostomy) tube
feeding, and diuretics (furosemide, hydrochlorothiazide,
spironolactone, torsemide, bumetanide, and metolazone)
were also checked and found to be insigniﬁcant. FBG was
measured in the early morning when patient activity levels
are very low, so activity also can be discounted as a possible
confounding factor.
To further assess the possible inﬂuence of the days-since-
injury range chosen, glucose and AFIM levels and glucose-
AFIM correlations were also determined for 0–20, 5–25,
10–30, 15–35, 20–40, 25–45, and 30–50 days since injury.
Strong glucose-AFIM correlations were observed regardless
of the range chosen. The range 0–30 is reported because
it most closely represents the Burke ischemic stroke patient
population.
3. Results
Atotalof361nondiabeticpatientswithFBGwithintherange
of70–130mg/dLwereincludedinthestudy.Descriptivedata
of these patients regarding age, gender, BMI, ethnic group,
AFIM,dayssincestroke,BP,bodytemperature,heartdisease,
atrial ﬁbrillation, and hypertension are listed in Table 1.Stroke Research and Treatment 3
Table 1: Basic characteristics of the patients.
No. of patients 361
Age, years (SD) 75.0 (12.9)
Gender, female (%) 188 (52.1)
Ethnic group (% Caucasian) 283 (78.4)
BMI (SD) 25.24 (5.2)
Average days since onset (median, SD) 9.4 (7, 6.2)
Initial stroke severity, admission FIM (SD) 55.7 (21.0)
Blood pressure, systolic, mmHg (SD) 132 (20)
Body temperature, degrees Fahrenheit (SD) 97.5 (1.1)
Body temperature, degrees Celsius (SD) 36.4 (0.6)
Atrial ﬁbrillation (%) 78 (21.6)
Heart disease (%) 45 (12.5)
Hypertension (%) 274 (75.9)
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Figure 1: Admission FIM scores versus fasting glucose concen-
tration. Lower admission FIM scores correspond to more severe
strokes. Error bars are standard errors. The Mann-Whitney P value
for the diﬀerence between lowest and highest glucose groups is
0.002. The P value for the slope of the glucose-admission FIM re-
gression line is 0.003.
FBG was measured on average 9.4 days (median 7 days)
after the acute stroke event.
Figure 1showstheunivariaterelationbetweenAFIMand
FBG in the range 70–130mg/dL. It appears from the ﬁgure
that decreasing AFIM (increasing stroke severity) is associ-
ated with increasing FBG within the entire 70–130mg/dL
range (correlation coeﬃcient −0.17; P<0.003).
Table 2 shows correlates of AFIM in our multiple linear
regression model. It appears that FBG signiﬁcantly correlates
with AFIM (partial correlation −0.165, CI −0.263 to −0.063,
P = 0.002). To check that the glucose-AFIM relationship
observed during multiple regression analysis was not due
to chance interactions between dependent and independent
variables, regression runs were conducted with diﬀerent
combinations of 3, 4, and 5 independent variables as well
as 11 independent variables shown in Table 2.R e g a r d l e s so f
the variables included, the FBG-AFIM relationship remained
strong. For example, for regression including AFIM, age,
gender, and FBG, the FBG-AFIM partial correlation coef-
ﬁcient was −0.176 (P = 0.0008); for regression including
Table 2: Variables associated with admission stroke severity (FIM)
linear-regression model parameters∗.
Partial correlation 95% conf. limits P value
Fasting blood glucose −0.165 −0.263 −0.063 0.002
Age −0.156 −0.254 −0.054 0.003
Gender −0.108 −0.209 −0.006 0.043
Ethnic group 0.045 −0.058 0.147 0.403
BMI 0.156 0.054 0.254 0.003
Systolic blood pressure 0.031 −0.072 0.133 0.562
Temperature −0.152 −0.251 −0.050 0.004
Days since stroke −0.349 −0.436 −0.256 0.000
Atrial ﬁbrillation −0.012 −0.115 0.091 0.822
Heart disease 0.022 −0.081 0.124 0.687
Hypertension 0.025 −0.078 0.127 0.644
∗Multiple R: 0.484167; R2: 0.234417.
AFIM, age, systolic blood pressure, and temperature, the
same partial correlation was −0.160 (P = 0.002); and for
regression including AFIM, age, gender, body mass index,
days since stroke, and FBG, corresponding results were
−0.174 (P = 0.001).
When records for patients with blood glucose at the high
end of the normal range (110–130mg/dL) were compared
to those at the low end (70 and 90mg/dL), the odds ratio
for more severe disability (below average AFIM score) was
2.02 (95% CI 1.10–3.73, P = 0.022). On average, there
was a decrease of 0.25 FIM points for each mg/dL increase
in blood glucose. Since a diﬀerence of four FIM points is
considered clinically signiﬁcant, each 16mg/dL increment in
blood glucose was thus associated with a clinically signiﬁcant
increase in impairment.
Analysis of diﬀerent days-since-injury ranges (0–20,5–
25,...,30–50) indicated that glucose levels did not change
signiﬁcantly. For 0–20 days since injury, average glucose
changed only from 108.9 to 106.0mg/dL.
4. Discussion
Our study shows that even in the normal range of FBG,
there is a signiﬁcant association between more severe strokes
and higher FBG one week after the stroke. As blood glucose
was measured at a time when the stress-induced BG increase
[12, 19–21, 23] is known to have resolved [7, 23, 24], our
study points to a graded association between higher glucose
concentrations and more severe stroke-induced brain injury.
Most studies point to a direct association between stroke
severity and BG concentrations at stroke onset [6–12]. In
these studies, the association was investigated and observed
only for BG in the hyperglycemic end of the BG spectrum
while the relation between stroke severity and BG within
the normal range of the spectrum has not been studied
before. In the aforementioned studies, BG was measured on
admission to hospital several hours after stroke onset but
still within the ﬁrst 24 hours of the stroke in the majority
of cases. At that time, BG is elevated in response to the stroke
incident [12, 19–21, 23]. Hence, BG measured at that time4 Stroke Research and Treatment
point cannot be taken to reﬂect the patients habitual BG
at stroke onset which is the more likely BG concentration
prevailing in the time period shortly after the stroke where
most irreversible brain damage takes place [16]. At one week
after stroke, FBG concentrations have declined and have
stabilized, and the FBG concentration may then reﬂect the
patient’s habitual BG concentration at the time of the stroke
[22]. We consider this the most likely explanation for the
strong association between stroke severity and FBG at one
week after the stroke seen in our study.
It is well known that outcome in stroke patients under-
going thrombolytic therapy is poorer in patients who are
hyperglycemic at the onset of treatment [11–13]. In the
ECASS-II trial [12], BG was measured within 6 hours and
repeated at 24 hours after the stroke. Whereas persistent
hyperglycemia (at baseline and at 24 hours after stroke)
was highly associated with poorer outcome, this was not
seen in patients in whom hyperglycemia only was transient
and present on the initial examination while not at the
24-hour examination. This observation may indicate that
the unfavorable inﬂuence of hyperglycemia on outcome is
seen only in the patients who are hyperglycemic already
at stroke onset rather than those who experience transient
hyperglycemia building up as a stress response in the
hours after the stroke. This observation also supports the
hypothesis that BG measured hours after stroke cannot be
taken to reﬂect the BG concentration at the time of stroke
onset which is more likely the BG concentration when most
irreversible brain damage takes place.
Thereiscompellingexperimentalandclinicalevidenceof
an association between hyperglycemia and poorer outcome
after stroke [6–13]. Our study now provides clinical evidence
indicating that higher FBG concentrations even within the
normoglycemic range are also associated with poorer out-
come. This is in line with numerous animal studies showing
at o x i ce ﬀect of higher glucose concentrations in ischemic
brain tissue in particular those demonstrating glucose as the
substrateforlactateformationintheischemic penumbra[1–
5].
Due to encouraging results of treatment regimes using
tight glucose control in management of critically ill patients
[28–30], current guidelines recommend lowering of BG at
least if high on admission [31]. However, attempts to repli-
cate the ﬁndings of promising previous reports have recently
failed, and concerns about safety have been raised as the
risk of inducing potentially harmful hypoglycemia appears
to be high in patients subjected to tight glucose control
regimens [32, 33]. To date, the GIST-UK trial [20] is the only
completed randomized study on glucose-lowering therapy
in stroke. This trial sought to determine whether treatment
with glucose-potassium-insulin infusion for 24 hours to
maintain normoglycemia within the range of 70–130mg/dL
mightreducedeathorseveredisabilityat90daysafterstroke.
The result of this study was negative; the investigators did
not ﬁnd evidence of a beneﬁcial eﬀect of insulin treatment
on death or disability after stroke, and concerns about
safety were raised as a number of patients required rescue
intravenous glucose treatment for hypoglycemic episodes.
Treatment was, however, instituted a mean of 13 hours after
the stroke at a time when most irreversible brain damage
already had taken place. Hence, the negative outcome of
the study does not preclude that higher BG at the time of
stroke may augment brain damage and increase initial stroke
severity. An alternate interpretation of this study is that
glucose lowering therapy should be initiated very early after
stroke onset (as is thrombolytic therapy).
A limitation to our study is the retrospective design
and that we only included patients eligible for a stroke
rehabilitation program. Therefore, patients in this study are
in the moderate range of the stroke severity spectrum, while
patients with very severe and mild strokes are relatively few.
Also patients who died within the ﬁrst week from stroke
onset were not included in our data, and very old patients
as well as previously severely handicapped patients may not
have been referred for rehabilitation. Our study population
is, however, large, and a multivariate analysis conﬁrmed
the FBG-stroke severity association with greater than 99%
conﬁdence. We therefore believe that our conclusions are not
aﬀected by selection bias to any signiﬁcant degree. The fact
that fasting blood glucose was measured at one week after
stroke instead of at the time of acute hospital admission is
considered an advantage of this study. We used a functional
score to measure stroke severity. Although this is not a
direct measure of the extent of the stroke lesion per se,
functional stroke scores have been shown to correlate closely
with lesion size [34]. We did not include patients with FBG
>130mg/dL and patients with diabetes in our study. First,
because it is already amply demonstrated by others [6–13]
that BG in nondiabetic patients with BG >130mg/dL is
directly associated with stroke severity, second a number
of patients with BG >130mg/dL may have prediabetes or
unmasked diabetes, and third it is already well known that
BG in patients with diabetes is not associated with stroke
severity [7, 24].
In conclusion, our study provides clinical evidence of
an association between more severe strokes and higher BG
even within the normoglycemic range following stroke. The
ﬁnding is, however, new and needs conﬁrmation in other
independentpopulationsbeforeenteringintoconsiderations
of clinical implications.
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